Page 16 - My FlipBook
P. 16
D’Souza, Deepak Cyril, 37 Food and Drug Administration,
Davies, Elisabeth, 34 US (FDA), 16, 17, 63, 71
decriminalization, as alternative Fowler, Caleb, 47–48
to legalization, 54–55
delta-9-tetrahydrocannabinol Galloway, Gantt, 27
(THC), 4 Gilman, Jodi, 40
brain regions affected by, Gladwell, Malcolm, 15
30–31, 33 Goodman, Luke, 47–48
levels in concentrated forms Guiding Good Choices, 56
of marijuana, 7
new marijuana and levels of, Hansen, Benjamin, 32
6, 25–26, 41 Harkey, David, 31
risk of cannabis use disorder Harvard Medical School,
with increased levels of, 26 30–31
Department of Health and Harvard University, 39
Human Services, US, 60 Harveland, Kaeden, 19, 20
Diagnostic and Statistical health risks
Manual of Mental cognitive impairment, 33–35
Disorders (DSM, American psychotic reactions, 41–42
Psychological Association), from vaping, 7
21–22, 23, 59 Herkov, Michael, 61
Di Forti, Marta, 62 Hicks, Brian, 26, 55
driving, effects of marijuana Hudek, Joseph Daniel, IV, 42,
on, 31–32 46
drug dependence, prevalence
among marijuana users vs. In-Shape program, 56
users of other substances, Institute of Medicine (IOM), 23
23 Insurance Institute for Highway
Drug Policy Alliance (DPA), 70 Safety, Highway Loss Data
Institute (IIHS-HLDI), 31
Encompass program, 56–57
endocannabinoids, 30 Jakaovljeveic, Anna, 45
Epidiolex, 16
Keepin’ it REAL program, 56,
family therapy, 61 57
75
